ReviewAnnals of translational medicine2019
Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects.
Review in Annals of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Comparative efficacy of pharmacological interventions on metabolic and hormonal outcomes in polycystic ovary syndrome: a Network Meta-Analysis of Randomized controlled trials.BMC women's health · 2025Pooled it
- Gastric cancer after Bariatric Bypass Surgery. Do they relate? (A Systematic Review).Obesity surgery · 2023Pooled it
- Assessing the efficacy of herbal supplements for managing obesity: A comprehensive review of global clinical trials.Iranian journal of basic medical sciences · 2025Review
- Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD).Journal of clinical & translational endocrinology · 2024Review
- Obesity: An Overview for the Interventional Radiologist.Seminars in interventional radiology · 2024Review
- Anti-Obesity Effects of Chitosan and Its Derivatives.Polymers · 2023Review
- Interventional metabology: A review of bariatric arterial embolization and endovascular denervation for treating metabolic disorders.Journal of diabetes · 2023Review
- Targeting activin receptor-like kinase 7 ameliorates adiposity and associated metabolic disorders.JCI insight · 2023Article
- The effects of E'Jiao on body composition, bone marrow adiposity and skeletal redox status in ovariectomised rats.International journal of medical sciences · 2023Article
- Roles of Gut Microbiome in Bone Homeostasis and Its Relationship with Bone-Related Diseases.Biology · 2022Review
- Treatments for obesity in the context of nonalcoholic steatohepatitis and mental health.Clinical liver disease · 2022Review
- Regulation of appetite-related neuropeptides by Panax ginseng: A novel approach for obesity treatment.Journal of ginseng research · 2022Review
- Regulatory mechanisms of the early phase of white adipocyte differentiation: an overview.Cellular and molecular life sciences : CMLS · 2022Review
- Therapeutic potential of α7 nicotinic acetylcholine receptor agonists to combat obesity, diabetes, and inflammation.Reviews in endocrine & metabolic disorders · 2020Review
- Microbiota-Mitochondria Inter-Talk: A Potential Therapeutic Strategy in Obesity and Type 2 Diabetes.Antioxidants (Basel, Switzerland) · 2020Review
- Tea polyphenols attenuate liver inflammation by modulating obesity-related genes and down-regulating COX-2 and iNOS expression in high fat-fed dogs.BMC veterinary research · 2020Article
- Systemic Nanoparticle-Mediated Delivery of Pantetheinase Vanin-1 Regulates Lipolysis and Adiposity in Abdominal White Adipose Tissue.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Current Long-Term Pharmacotherapies for the Management of Obesity.Journal of obesity & metabolic syndrome · 2020Review
- Biobehavioural approaches to prevention and treatment: A call for implementation science in obesity research.Obesity science & practice · 2020Article
- A Systematic Review of the European Rapid Alert System for Food and Feed: Tendencies in Illegal Food Supplements for Weight Loss.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a chronic, relapsing, multifactorial disease, which has become a serious threat to public health globally, as the worldwide prevalence of obesity increases exponentially over time. It has been well established that obesity is associated with multiple adverse cardiometabolic effects. Although lifestyle changes are the first line of therapy for obesity, these are often insufficient in attaining weight loss goals. Orlistat, phentermine/topiramate, lorcaserin, naltrexone/bupropion, and liraglutide are agents that have been approved for the treatment of obesity but their effects on cardiometabolic risk factors and outcomes have not been clearly elucidated. Given the detrimental repercussions of obesity on cardiometabolic health, there is a pressing clinical need to fully understand the effects of these agents beyond weight loss alone. Certain previous weight loss drugs have been withdrawn due to safety concerns and this underlines the need for more careful assessment of the effects of the various pharmacologic agents currently used for the treatment of obesity. This review aims to provide an overview of the mechanisms, efficacy, safety and cardiometabolic effects of the currently available pharmacologic agents for weight loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.